United States · Biotechnology startup
United States · Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Funding reportedLast round: Post-IPO Equity
What company datasets say Atara Biotherapeutics raised
Funding, as reported
Reported in all$550Kin dollars
Last roundPost-IPO Equity
Investors listed5
Founders and team
From Atara Biotherapeutics's own website: 8 on the team.
- Jim SesicSenior Vice President, Regulatory Affairs
- Kevin SarneyInterim Chief Financial Officer
- Brian CherryDirector
- Gregory A. CiongoliChairman of the Board
- James HuangDirector
- Matthew FustDirector, Audit Committee Chair
- Nachi SubramanianDirector
- William HeidenDirector, Compensation Chair
On 2 portfolio pages
Investors who name them
Each firm lists Atara Biotherapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Atara Biotherapeutics in front of investors. Or tell us what we have wrong.